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Objectives This study sought to improve methodology for predicting post–percutaneous coronary
intervention (PCI) mortality.
Background Recently, an increased proportion of post-PCI deaths caused by noncardiac causes has
been suggested, often in rapidly triaged patients resuscitated from sudden cardiac death or presenting
with cardiogenic shock. Older risk adjustment algorithms may not adequately reﬂect these issues.
Methods Consecutive patients undergoing PCI from 2000 to 2009 were randomly divided into
training (n  8,966) and validation (n  8,891) cohorts. The 2010 ACC-NCDR (American College of
Cardiology–National Cardiovascular Data Registry) mortality algorithm was applied to the training
cohort and its highest risk decile, separately. Variables describing general and neurological status at
admission were then tested for their additional predictive capability and new algorithms developed.
These were tested in the validation cohort, using receiver-operator characteristic curve, Hosmer-
Lemeshow, and reclassiﬁcation measures as principal outcome measures.
Results In-hospital mortality was 1.0%, of which 52.2% had noncardiac causes or major contribu-
tions. Baseline model C-statistics for the total and upper decile training cohorts were 0.904 and
0.830. The Aldrete score (addressing consciousness, respiration, skin color, muscle function, and cir-
culation) and neurology scores added incremental information, resulting in improved validation co-
hort C-statistics (entire group: 0.883 to 0.914, p  0.001; high-risk decile: 0.829 to 0.874, p  0.001).
eclassiﬁcation of the ACC-NCDR 90th and 90th risk percentiles by the new score yielded im-
roved mortality prediction (p  0.001 and p  0.033, respectively).
onclusions Half of in-hospital deaths in this series were of noncardiac causation. Prediction of in-
ospital mortality after PCI can be considerably improved over conventional models by the inclusion
f variables describing general and neurological status. (J Am Coll Cardiol Intv 2011;4:442–8)
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443Publicly available comparison of hospital outcomes has been
advocated to improve both hospital quality and patient out-
comes (1). Appropriate comparison requires risk adjustment
odeling. Models to allow for comparison of mortality after
ercutaneous coronary intervention (PCI) have been refined
ver the past 2 decades (2). Perhaps the most widely used
model is that by the ACC/NCDR (American College of
Cardiology–National Cardiovascular Registry) (2,3). Al-
though an excellent model by current standards when initially
See page 449
tested, it derives from a database originally intended to
categorize variables and outcomes most directly related to
the procedure itself and its cardiac outcomes. As noncardiac
mortality has assumed an increasingly relative role in overall
in-hospital mortality, onemight postulate the addition of variables
that might relate to noncardiac mortality in this setting might
provide incremental prognostic and adjustive value.
Methods
Study population and clinical end point. All data were re-
rieved from our Institutional Review Board–approved coro-
ary interventional database. Consecutive patients treated for
Figure 1. Components and Scoring System for the Aldrete and
Neurological ScoresAldrete score is the sum of its 5 individual categories. BP  blood pressure.he first time at our institution from January 2000 through
ecember 2009 were studied. Patients were divided into a
evelopmental cohort (n 8,966) and a validation cohort (n
,891) using a random number generator. Data were coded by
rained cardiologists and nurses according to American College
f Cardiology definitions, and cross-validated by a trained
adre of research nurses. For patients who expired, specific data
ere recorded on dedicated report forms, and a hospitalization
ummary was prepared by 1 of the trained research nurses.
inal adjudication was performed by 1 of the authors (S.G.E.).
Statistical analyses. We initially applied the ACC/NCDR
basic pre-catheterization model for in-hospital death following
PCI (3) to the developmental cohort (the full model was not
used as certain variables [e.g., subacute thrombosis] had not
been captured for the entirety of the data collection period).
The following variables were then tested for additional
prognostic value using multivariate logistic regression analyses
with backward elimination and a retention p value 0.05:
ldrete score (originally formulated to evaluate recovery from
nesthesia) (4) (Fig. 1), neurological score (both scores being
outinely coded by the catheterization laboratory nurses before
he procedure), and cardiac arrest within the preceding 24 h
efore PCI. A final model was constructed using the variable
oefficients as multipliers for each variable in the additive
odel.
The developed models were
hen applied to the validation co-
ort with significance testing eval-
ated between ACC-NCDR and
he new models’ discrimination.
To assess model discrimination, we calculated the C-statistic
5). Hosmer-Lemeshow testing was performed across deciles
f risk to assess calibration (6). Reclassification testing was
re-specified using the validation cohort’s ACC-NCDR
90th and 90th percentiles, testing improvement in corre-
ation with mortality with the new models. Net reclassification
ndex (7) was also calculated.
A similar strategy was applied separately to the highest risk
ecile determined by ACC-NCDR risk modeling, except
osmer-Lemeshow statistics were assessed across quintiles
because there were fewer patients evaluated).
All tests were 2-sided. A value of p  0.05 was considered
ignificant for all tests. Statistical calculations were performed
sing a statistical program (SYSTAT, Version 11, Systat
ystems, Richmond, California).
esults
Baseline demographics, treatments, and summary outcomes
for the training and validation cohorts are shown in Table 1.
The incidence of cardiac arrest before the time of starting
Abbreviation
and Acronym
PCI  percutaneous
coronary interventionPCI increased from 0.6% during 2000 to 2003, to 0.85%
rv
V
m
Stent treatment 88.7 88.7
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444during 2004 to 2006, and to 1.88% during 2007 to 2009
(p  0.001). In-hospital mortality for those 3 periods was
1.0%, 0.8%, and 1.3%, respectively. Overall mortality in the
entire cohort was 1.0% and, since we began coding causes of
death in 2007, 52.2% were of noncardiac cause (31.2%
neurological or with major neurological contribution, 8.3%
pulmonary, 6.3% bleeding).
In the training sample, Aldrete score, individual compo-
nents of the Aldrete score, cardiac arrest, and the neurolog-
ical score were each individually highly correlated with
mortality (Fig. 2, Table 2).
Independent correlates of in-hospital death found by
multivariate testing in the training cohort for the entire
group and the high-risk decile are shown in Tables 3 and 4,
espectively.
C- and Hosmer-Lemeshow statistics for the training and
alidation, global, and high-risk cohorts are shown in Table 5.
alidation cohort C-statistics were improved with the new
odel in both the entire and highest risk decile cohorts
Table 1. Continued
Training
(n  8,966)
Validation
(n  8,891)
Outcome
Emergency CABG 0.2 0.3
In-hospital death 0.9 1.0
Procedural success 96.8 97.0
Q-wave MI 0.2 0.2
Values are mean SD or %.
ACE angiotensin-converting enzyme; CABG coronary artery bypass graft; COPD chronic
obstructive pulmonary disease; GFR glomerular filtration rate; LAD left anterior descending;
LCX  left circumflex; LMT  left main trunk; LVEF  left ventricular ejection fraction; MI 
myocardial infarction; RCA right coronary artery; SCAI Society for Cardiac Angiography and
Interventions; STEMI ST-segment elevation myocardial infarction.
Figure 2. Relation of the Aldrete Score to In-Hospital Mortality
Relation of the Aldrete score to in-hospital mortality in the entire patientTable 1. Baseline Characteristics: Treatment and In-Hospital Outcomes in
the Training and Validation Cohorts
Training
(n  8,966)
Validation
(n  8,891)
Baseline
Age, yrs 65.1  11.6 64.7  11.6
Aldrete score 9.5  1.2 9.5  1.1
Cardiac arrest 1.0 1.0
Cardiogenic shock 0.8 0.8
Cerebrovascular disease 10.8 11.1
COPD 12.6 12.5
Diabetes 36.1 35.8
GFR, ml/min 73.3  26.1 73.4  26.2
Hypercholesterolemia 47.2 47.0
Hypertension 66.4 66.4
LVEF 49  12 50  12
Male sex 70.5 70.6
Neurological status 0–1 1.0 1.0
Non-STEMI 24 h 5.5 5.2
Number of diseased vessels 1.5  0.7 1.5  0.7
Peripheral arterial disease 13.8 13.5
Prior CABG 43.5 43.6
Prior MI 33.1 34.0
Renal insufﬁciency 6.1 5.9
Smoking
Current 16.4 16.5
Past 50.4 50.0
STEMI 24 h 4.6 4.5
Unstable angina 41.5 41.0
Treatment
Pre-treatment/treatment medication
ACE inhibitors 48.8 47.9
Beta blockers 71.6 71.4
Bivalirudin 44.6 44.6
Statins 79.8 79.7
Procedural status
Emergent 8.0 7.5
Salvage 0.3 0.2
Urgent 19.2 19.3
Treated site(s)
LAD 43.5 43.8
LCX 37.9 39.2
LMT 5.2 5.4
RCA 38.7 38.5
Number of lesions 1.7  1.0 1.8  1.0
SCAI
II 25.4 25.1
III 1.9 1.8
IV 10.5 10.9cohort.
p
t
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445(both p 0.001) (Table 5). Reclassification by the new score
in the validation cohort led to improved discrimination for
mortality (ACC-NCDR 90th percentile reclassified to 90th
percentile, no vs. yes: 0.17% vs. 2.87% mortality, p 0.001; and
ACC-NCDR 90th percentile reclassified to90th percentile,
yes vs. no: 0.86% vs. 4.50% mortality, p  0.033). The net
reclassification index  0.141.
The new score performed comparably in the ST-segment
elevation myocardial infarction and non–ST-segment ele-
vation myocardial infarction populations (C-statistics: 0.861
and 0.898, respectively; interaction: p  0.31), but did not
erform as well in the salvage as in the nonsalvage popula-
ion (C-statistics: 0.754 and 0.902, respectively; p 0.001).
Discussion
The principal findings of this study include: 1) In recent
years, more than half of PCI-related in-hospital mortality
appears to be due to, or has a large component related to,
noncardiac causes. 2) Somewhat similar to other recent
reports (8), the current ACC-NCDR in-hospital mortality
model has very good, but not excellent, predictive capability
as measured by receiver-operator characteristic testing (especially
at the upper end of risk). 3) The addition of the easy-to-collect
Aldrete score characterizing general patient status, and a simple
neurological score, to the ACC-NCDR model appreciably im-
proves prediction of in-hospital mortality.
The potential benefit of public reporting of risk-adjusted
clinical outcomes is clear (1). Interventional cardiologists,
taking the lead from our surgical colleagues, began sophis-
Table 3. Correlates of In-Hospital Mortality in the Entire Training Cohort
Variable Estimate SE OR 95% CI t Ratio p Value
ACC-NCDR score 0.692 0.056 2.00 1.79–2.33 12.30 0.001
Aldrete 8 1.754 0.225 5.78 3.71–8.98 7.78 0.001
Aldrete 5 0.879 0.359 2.41 1.19–4.87 2.45 0.014
Neuro 1 0.781 0.348 2.18 1.11–4.32 2.25 0.025
Constant 7.292 0.218 — — 33.52 0.001
ACC-NCDR American College of Cardiology–National Cardiovascular Data Registry; CI confi-
Table 2. Relation of Cardiac Arrest, Aldrete Score, and Its Neurological
Component to In-Hospital Death in the Entire Cohort
% Patients
% Mortality
% PARWith Without
Cardiac arrest 0.62 20.00 0.86 12.64
Neuro 0 0.64 34.21 0.76 22.41
Neuro 0–1 0.98 25.14 0.74 25.29
Aldrete 0–5 0.87 26.14 0.87 23.26
0–8 16.11 4.78 0.24 79.07
Neuro neurological status; PAR population attributable risk.dence interval; OR odds ratio; SE standard error; other abbreviations as in Table 2.ticated efforts to risk-adjusted outcomes in the 1990s
(9–11). Typically, with the exception of renal failure, these
models included only variables related to cardiac status
(9–12). Nonetheless, at least using the metric of the
C-statistic (13), these models achieved very good to excel-
lent prediction of risk among general populations. Whereas
these models have been refined over the years (3), they
have continued to focus principally on cardiac-specific
variables and, in their relation with mortality, have
reported C-statistics between 0.82 and 0.92 (2,3,9 –11).
Despite this, there remain concerns in both the clinical
community and among clinician researchers that models
do not adequately address risk adjustment for patients at
the highest risk (14,15). Perhaps as a consequence, there
have been several reports of physician avoidance of
high-risk patients once outcomes became reported pub-
licly (e.g., dramatic reduction in patients with cardiogenic
shock treated with PCI in Massachusetts between 2003
and 2005) (16,17).
Resnic and Welt (16) were perhaps the first to draw
attention to the fact that much of the in-hospital mortality
after PCI is no longer related to the procedure. In their
study of the Brigham and Women’s Hospital’s (2003 to
2005) experience, 45% of patients who died had at least 1
Table 4. Correlates of In-Hospital Mortality in the High-Risk Decile* of
the Training Cohort
Variable Estimate SE OR 95% CI t Ratio p Value
ACC-NCDR score 0.662 0.061 1.94 1.72–2.18 10.86 0.001
Aldrete 8 1.378 0.236 3.97 2.49–6.29 5.86 0.001
Aldrete 5 0.972 0.244 2.64 1.64–4.26 3.99 0.001
Constant 6.668 0.343 — — 19.45 0.001
*As defined by ACC-NCDRmodel (3).
Abbreviations as in Table 3.
Table 5. C- and Hosmer-Lemeshow Statistics
C-Statistic HL p Value
ACC–NCDR
Training cohort
Entire 0.904 0.64
High-risk 0.830 0.51
Validation cohort
Entire 0.883 0.58
High-risk 0.829 0.43
New model
Validation cohort
Entire 0.914* 0.75
High-risk 0.874* 0.30
*p 0.001 versus ACC-NCDR C-statistic.HL Hosmer-Lemeshow; other abbreviations as in Table 3.
0.00
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446severe acute medical condition not accounted for by data
collection in the ACC-NCDR registry, and 42% of patients
died of a noncardiac cause.
The results of several key clinical trials: establishing the
superiority of PCI over fibrinolysis (18), suggesting lesser
need for revascularization in modestly symptomatic patients
(19,20), and the survival benefit for cooling of cardiac arrest
patients (21,22) (leading to more aggressive treatment of
Figure 3. ROC Curves for the Validation and High-Risk Decile Validation Co
Receiver-operator characteristic (ROC) curves for the (A) validation and (B)
Cardiology—National Cardiovascular Data Registry). Dotted lines: new mo
high-risk decile were 0.883 and 0.914 (p  0.001) and 0.829 and 0.874 (p 
Figure 4. Calibration of the ACC-NCDR and New Models in the Overall and
Risk by decile and Hosmer-Lemeshow statistics for the overall validation cohor
observed mortality; solid boxes  predicted mortality. Hosmer-Lemeshow p v
tions as in Figure 3.these very ill patients) has changed the nature of patients
undergoing PCI. In fact, PCI within 24 h of acute myo-
cardial infarction has increased from 18.5% in 1999 to
31.8% in 2009 of all cases reported to the ACC-NCDR
(23). Concomitantly, the improving technical and pharma-
cological armamentarium available to the interventionalist
has reduced the ischemic complications of PCI (24). It
would not be surprising, therefore, if the clinical correlates
risk decile validation cohorts. Solid lines: ACC-NCDR (American College of
statistics for the ACC-NCDR and new model for the entire validation and
1), respectively.
Risk Validation Cohorts
) and for the high-risk decile validation cohort (C, D). Open boxes 
for (A) through (D) were 0.58, 0.75, 0.43, and 0.30, respectively. Abbrevia-horts
high-
del. C-High-
t (A, B
alues
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447of PCI-related mortality have changed somewhat over the
last decade.
Several investigators have noted the difficulty in increas-
ing a model’s C-statistic with the addition of highly
significant parameters with odds ratios of 3 or even higher
(7,13,25). As an example, the difference in Framingham risk
score with or without the variable current smoking (risk
ratio [RR]: 2.9) in the Women’s Health Study data (n 
26,901) was only 0.76 versus 0.78 (26). The present model
improves on the ACC-NCDR model with discrimination
(C-statistic) increasing by 0.031 and 0.045 in the entire
validation and high-risk decile validation cohorts, respec-
tively, without loss of calibration (Hosmer-Lemeshow sta-
tistic). Reclassification tests show significant improvement
in prediction mortality also.
Importantly, the model is most appreciably improved
for patients at the highest decile of risk. That said,
accurately assessing risk at the very high end of the risk
spectrum (e.g., the 0.5% of all patients undergoing
“salvage” procedures with 44% mortality) is a particular
challenge. Perhaps such patients should be excluded from
scorecarding altogether.
Study limitations. This study has several limitations. First, it
derives from the experience of a single institution and hence
will require external validation. Second, accurate prediction
of risk for the highest risk patient remains a challenge.
Despite the fact that factors such as poor neurological
status (neurological score 0 to 1) increase the risk of
mortality over 30-fold, the highest risk percentile of
patients only have a 35% predicted mortality, and it is not
until risk scores get into the upper fraction of this
percentile that expected mortality exceeds 50%. The vast
majority of patients undergoing PCI are low risk (75%
have predicted mortality less than 0.5%) (Fig. 3B). Third,
follow-up through hospital discharge allows analysis only
of a short window in time. Better models evaluating
long-term outcomes are needed. Lastly, we could not
assess the influence of Aldrete score on the full ACC-
NCDR model for reasons noted in the Methods section.
However, there is little reason to think that the addition of
general and neurological assessments would not add additional
prognostic information in that the full ACC-NCDR model
does not contain any variables touching on clinical parameters
evaluated by the Aldrete score (Fig. 4).
Conclusions
Accurate prediction of risk for patients undergoing PCI
should improve patient selection for this procedure and
facilitate appropriate comparison of outcomes among oper-
ators and among hospital systems. Our results suggest that
routine, accurate, and monitored collection of data relat-
ing to the patient’s general and neurological status before
PCI should become standard as we attempt to improveoverall patient care. Appreciation of this fact should be
considered as only 1 step in the iterative process of
healthcare improvement in the field of interventional
cardiology.
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